Daratumumab (dara), trade name Darzalex, received breakthrough therapy drug status in 2013 for multiple myeloma. Daratumumab is a monoclonal antibody directed against CD38, a molecule present on myeloma cells. Since it’s inception, it has taken the myeloma world by storm. In late 2015 daratumumab was approved by the U.S. Food and Drug Administration (FDA) for treatment of […]